Tau NonTangles™ – small molecule for Alzheimer’s disease treatment is associated with clinical signs consistent with improvements in motor symptoms.

BUSAN, YEONGNAM, SOUTH KOREA, December 8, 2019 /⁨EINPresswire.com⁩/ — Biogenum (ISIN: …
Biogenum Announces Favorable Safety Profile for Tau NonTangles™ in a Phase 1/2 Clinical Trial in Patients with Alzheimer